NewAmsterdam Pharma to Host Investor Day on August 5, 2026

Rhea-AI Summary

NewAmsterdam Pharma (Nasdaq: NAMS) will host an Investor Day on August 5, 2026, beginning at 9:00 a.m. ET in New York City, featuring presentations from its CEO, founder/CSO, CCO, CFO and Head of Investor Relations.

A live webcast with supporting presentation materials will be accessible via the Events section of NewAmsterdam’s investor relations website, with an archived replay available afterwards. In-person attendance requires advance registration. The company will discuss obicetrapib, its late-stage, oral CETP inhibitor, including ongoing Phase 3 programs such as the PREVAIL cardiovascular outcomes trial.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NAARDEN, The Netherlands and MIAMI, July 29, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that it will host an Investor Day event for analysts and investors on August 5, 2026 beginning at 9:00 a.m. ET in New York City.

Please join members of our management team, including: Michael Davidson, M.D., Chief Executive Officer; John Kastelein, M.D., Ph.D., FESC, Founder and Chief Scientific Officer; BJ Jones, Chief Commercial Officer; Ian Somaiya, Chief Financial Officer; and Matthew Philippe, Executive Vice President and Head of Investor Relations.

A live webcast of the Investor Day event will be available, and those who intend to join virtually can pre-register for the webcast through the link here. The live webcast and supporting presentation materials will be available on the Events section of the Investor Relations page of the NewAmsterdam website at ir.newamsterdampharma.com at the time of the live event. An archived replay will be available on the NewAmsterdam website. Please note advanced registration is required for in-person attendance.

About Obicetrapib
Obicetrapib is a novel, oral, low-dose CETP inhibitor that NewAmsterdam is developing to overcome the limitations of current LDL-lowering treatments. In each of the Company’s Phase 2 trials, ROSE2, TULIP, ROSE, and OCEAN, as well as the Company’s Phase 3 BROOKLYN, BROADWAY and TANDEM trials, evaluating obicetrapib as monotherapy or combination therapy, the Company observed statistically significant LDL-lowering combined with a side effect profile similar to that of placebo. The Company commenced the Phase 3 PREVAIL cardiovascular outcomes trial in March 2022, which is designed to assess the potential of obicetrapib to reduce occurrences of MACE. The Company completed enrollment of PREVAIL in April 2024 and randomized over 9,500 patients. Commercialization rights of obicetrapib in Europe, either as a monotherapy or as part of a fixed-dose combination with ezetimibe, have been exclusively granted to the Menarini Group, an Italy-based, leading international pharmaceutical and diagnostics company.

About NewAmsterdam
NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well-tolerated and convenient therapy that lowers LDL-C while advancing innovation beyond a single marker to better address cardiovascular risk. In multiple phase 3 trials, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose combination with ezetimibe, as LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated.

Company Contact
Matthew Philippe
P: 1-917-882-7512
matthew.philippe@newamsterdampharma.com

Media Contact
Real Chemistry on behalf of NewAmsterdam
Christian Edgington
P: 1-513-310-6410
cedgington@realchemistry.com

Investor Contact
Precision AQ on behalf of NewAmsterdam
Austin Murtagh
P: 1-212-698-8696
austin.murtagh@precisionaq.com

FAQ

When is NewAmsterdam Pharma's (NAMS) Investor Day in 2026 and what time does it start?

NewAmsterdam Pharma’s Investor Day is scheduled for August 5, 2026, starting at 9:00 a.m. ET. According to NewAmsterdam, the event will be held in New York City and is aimed at analysts and investors.

How can investors access the NewAmsterdam Pharma (NAMS) Investor Day 2026 webcast?

Investors can access a live webcast of NewAmsterdam Pharma’s August 5, 2026 Investor Day through the Events section of its investor relations website. According to NewAmsterdam, pre-registration is available and an archived replay will also be posted on the company’s website.

Is in-person attendance allowed at NewAmsterdam Pharma's Investor Day on August 5, 2026?

In-person attendance at NewAmsterdam Pharma’s August 5, 2026 Investor Day is allowed but requires advanced registration. According to NewAmsterdam, the event will take place in New York City and is designed for analysts and investors.

What will NewAmsterdam Pharma (NAMS) present about obicetrapib at the 2026 Investor Day?

NewAmsterdam is expected to discuss obicetrapib, its oral, low-dose CETP inhibitor in Phase 3 development. According to NewAmsterdam, obicetrapib has shown statistically significant LDL-C lowering with placebo-like side effect profiles in prior trials and is being evaluated in the PREVAIL cardiovascular outcomes study.

What is the PREVAIL cardiovascular outcomes trial mentioned by NewAmsterdam Pharma (NAMS)?

PREVAIL is NewAmsterdam’s Phase 3 cardiovascular outcomes trial evaluating obicetrapib’s impact on major adverse cardiovascular events (MACE). According to NewAmsterdam, enrollment was completed in April 2024, with over 9,500 patients randomized after commencing the study in March 2022.

Who are the key speakers at NewAmsterdam Pharma's Investor Day on August 5, 2026?

Key speakers include CEO Michael Davidson, Founder and CSO John Kastelein, CCO BJ Jones, CFO Ian Somaiya, and Head of Investor Relations Matthew Philippe. According to NewAmsterdam, these executives will present to analysts and investors during the event.